-- Earnings Flash (ORGS) ORGENESIS Posts Q1 EPS $0.16
7:01AM ET 5/24/2022 MT Newswires...
Quotes Snapshot > ORGS
Orgenesis Inc ORGS:NASDAQ
Last Price$2.42NASDAQ Closing Price as of 4:00PM ET 6/30/22
Today's Change-0.10(3.97%)
Bid (Size)$2.36 (5)
Ask (Size)$2.42 (6)
Day Low / High$2.26 - 2.50
Volume17.0 K
Read more news Recent News
Orgenesis Launches $14.8 Million Private Placement
7:42AM ET 3/31/2022 MT NewswiresOrgenesis (ORGS) said Thursday that it agreed to sell 4,933,333 shares of common stock in a private placement at $3 per share and warrants to purchase up...
Orgenesis, Theracell Joint Venture to Receive up to $36 Million From Greek Government; Shares Rise Pre-Bell
8:24AM ET 11/29/2021 MT NewswiresOrgenesis (ORGS) said Monday that its joint venture with Theracell Advanced Biotechnology in Greece has been designated a "Priority Investment of Strategic...
View all Commentary and Analysis
Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript
10:50PM ET 3/30/2022 Seeking AlphaOrgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript
4:42PM ET 11/06/2021 Seeking AlphaOrgenesis (ORGS) Investor Presentation - Slideshow
3:23PM ET 8/23/2021 Seeking AlphaCompany Profile
Business DescriptionOrgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD. View company web site for more details
| Address | 20271 Goldenrod Lane Germantown, Maryland 20876 |
| Phone | +1.480.659.6404 |
| Number of Employees | 231 |
| Recent SEC Filing | 06/16/2022 4 |
| Chairman, President & Chief Executive Officer | Vered Caplan |
| Chief Financial Officer, Secretary & Treasurer | Neil Reithinger |
| Chief Scientific Officer | Sarah Ferber |
| Medical Director | Heiko von der Leyen |
Company Highlights
| Price Open | $2.50 |
| Previous Close | $2.52 |
| 52 Week Range | $1.77 - 5.49 |
| Market Capitalization | $60.1 M |
| Shares Outstanding | 24.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.90 |
| Beta vs. S&P 500 | N/A |
| Revenue | $18.7 M |
| Net Profit Margin | -65.55% |
| Return on Equity | -52.11% |
Analyst Ratings as of 04/19/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |